Hi everyone! I recently moved to the US from England and am currently looking for work in the Boston, MA area. I have 4+ years experience in PBPK modelling across a range of therapeutic applications including drug interactions, special populations and long-acting nanomedicine...
...I am highly proficient in Matlab Simbiology with additional experience in GastroPlus. I am interested in applying PBPK modelling strategies to answer novel therapeutic questions and furthering my skills across QSP software platforms...
We are delighted to publish our #PBPK model for dose escalation of ritonavir-boosted atazanavir to overcome the interaction with rifampicin. The clinical trial is underway: initial results presented at #EDCTPforum this week support model accuracy.
https://t.co/PVLpKfO8nQ
Congratulations to @HMKinvig who passed her PhD viva with minor corrections this afternoon. Innovative work to integrate experimental and computational approaches for the prediction of drug-drug interactions. HIV, TB, Hep C and leprosy drugs including RIF, DTG, ATV/r and more.
So incredibly proud of @OhKatSchneider and team for receiving an Oculus Launch Pad grant for the Potluck VR experience! Can't wait to learn how to cook virtual reality sushi from Japanese chef Yohei Kamiya!
We’re excited to introduce the 2020 Launch Pad grant recipients and their VR projects that are helping to push the industry in exciting new directions. Today we're opening applications to join Oculus Launch Pad 2021--apply now! https://t.co/xbxNWAV4Ml
Proud to be a part of #vCROI2021 this year presenting our work on the in silico prediction of monthly bictegravir microneedle array patches. Using PBPK modelling we found bictegravir to be a promising candidate for once-monthly administration with practical patch sizes.
Excellent talk by Dr Shahin Lockman highlighting the lack of data for HIV treatment in pregnancy and that "exclusion from research does not remove risk, but simply shifts risk". #vCROI2021
Now available to all on YouTube: the vCROI 2021 Martin Delaney Presentation, “Vaccine Nationalism Is Killing Us: How Inequities in Research and Access to SARS-CoV-2 Vaccines Will Perpetuate the Pandemic.” https://t.co/uJySj7JJU6
Grateful for the opportunity to share the progress we are making by combining in vitro techniques and PBPK modelling to support the clinical management of people living with HIV #WorldAIDSDay
The fight against #HIV can be challenging - here how @HMKinvig at the @LivUniISMIB@LivUni is developing innovative methods to improve understanding of drug interactions and to support novel formulations #WorldAIDSDay https://t.co/3EOjxXmHig
Fascinating presentation from @HMKinvig showing how drug transporter expression is different in the elderly, which may result in different risks of drug-drug interactions. It is essential to study drugs in the population where they will be used - elderly among the most neglected!
The complexity of identifying #drugs against #Covid_19: are we asking the right questions for effective answers? Our brainstorm analysis with @daveback01, J. Shapiro and Gianni Di Perri on @BSACandJAC. @LivUniISMIB https://t.co/0SL3BRFL6d
Presenting my #CROI2020 poster virtually this year! I used PBPK modelling to predict the drug-drug interaction between high dose once monthly rifampicin and several dolutegravir regimens #virtualCROI2020
Alfie and I tuning into Fazila Bunglawala's #CROI2020 talk on the identification of age-appropriate dosing strategies of bictegravir in neonates! Well done!